{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:42:00Z","timestamp":1768293720534,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1157\/13125587","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T02:35:24Z","timestamp":1221100524000},"page":"421-426","source":"Crossref","is-referenced-by-count":25,"title":["Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response"],"prefix":"10.1016","volume":"31","author":[{"given":"Yago","family":"Gonz\u00e1lez-Lama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"L\u00f3pez-San Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Mar\u00edn-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Casis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"L\u00e1zaro P\u00e9rez-Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Taxonera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Mart\u00ednez-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Mench\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Mart\u00ednez-Montiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Antonio Carneros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Luis Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Mar\u00eda Milicua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala\u00edn","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"L\u00f3pez-Palacios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Mat\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier P.","family":"Gisberta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13125587_bb0010","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1157\/13125587_bb0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1157\/13125587_bb0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/00365529509096316","article-title":"Disease activity courses in a regional cohort of Crohn's disease patients","volume":"30","author":"Munkholm","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1157\/13125587_bb0025","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0016-5085(98)70420-2","article-title":"Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients","volume":"114","author":"Lapidus","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1157\/13125587_bb0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn's disease with 6- mercaptopurine. A long-term, randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1157\/13125587_bb0035","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1157\/13125587_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0140-6736(96)90402-X","article-title":"Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine","volume":"347","author":"Bouhnik","year":"1996","journal-title":"Lancet"},{"key":"10.1157\/13125587_bb0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1157\/13125587_bb0050","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1157\/13125587_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/gut.2005.081950c","article-title":"European evidence based consensus on the diagnosis and management of Crohn's disease: special situations","volume":"55","author":"Caprilli","year":"2006","journal-title":"Gut"},{"key":"10.1157\/13125587_bb0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2004.045294","article-title":"Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery","volume":"54","author":"Cosnes","year":"2005","journal-title":"Gut"},{"key":"10.1157\/13125587_bb0065","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","article-title":"Optimizing anti-TNF treatment in inflammatory bowel disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1157\/13125587_bb0070","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/00003495-200565150-00014","article-title":"Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis","volume":"65","author":"Siddiqui","year":"2005","journal-title":"Drugs"},{"key":"10.1157\/13125587_bb0075","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2165\/00003495-200565160-00002","article-title":"Biologic therapy for inflammatory bowel disease","volume":"65","author":"Ardizzone","year":"2005","journal-title":"Drugs"},{"issue":"13 Suppl 4","key":"10.1157\/13125587_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2036.1999.00024.x","article-title":"Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease: the mechanisms of action of infliximab","author":"Van Deventer","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13125587_bb0085","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1157\/13125587_bb0090","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1157\/13125587_bb0095","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1157\/13125587_bb0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2006.02786.x","article-title":"Review article: infliximab therapy for inflammatory bowel disease: seven years on","volume":"23","author":"Rutgeerts","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13125587_bb0105","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00054725-199811000-00014","article-title":"Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference","volume":"4","author":"Kornbluth","year":"1998","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13125587_bb0110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","article-title":"Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients","volume":"96","author":"Ricart","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13125587_bb0115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1445-5994.2001.00039.x","article-title":"Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group","volume":"31","author":"Mortimore","year":"2001","journal-title":"Intern Med J"},{"issue":"Suppl 1","key":"10.1157\/13125587_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ibd.3780070505","article-title":"Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience","volume":"7","author":"Cohen","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13125587_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00054725-200203000-00002","article-title":"Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital","volume":"8","author":"Hommes","year":"2002","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13125587_bb0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1155\/2002\/379307","article-title":"Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta","volume":"16","author":"Sample","year":"2002","journal-title":"Can J Gastroenterol"},{"key":"10.1157\/13125587_bb0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1590-8658(02)80038-X","article-title":"Infliximab in treatment of Crohn's disease: the Milan experience","volume":"34","author":"Ardizzone","year":"2002","journal-title":"Dig Liver Dis"},{"key":"10.1157\/13125587_bb0140","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1365-2036.2002.01268.x","article-title":"Effects of antitumour necrosis factor-alpha therapy on the quality of life in Crohn's disease","volume":"16","author":"Van Balkom","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13125587_bb0145","first-page":"7","article-title":"Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania","volume":"12","author":"Gheorghe","year":"2003","journal-title":"Rom J Gastroenterol"},{"key":"10.1157\/13125587_bb0150","first-page":"48","article-title":"Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea","volume":"46","author":"Choi","year":"2005","journal-title":"Korean J Gastroenterol"},{"key":"10.1157\/13125587_bb0155","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00054725-200411000-00008","article-title":"Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease","volume":"10","author":"Lamireau","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1157\/13125587_bb0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.meg.0000108355.41221.77","article-title":"Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up","volume":"16","author":"Wenzl","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1157\/13125587_bb0165","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1572-0241.2003.07161.x","article-title":"Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center","volume":"98","author":"Stephens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13125587_bb0170","first-page":"269","article-title":"Infliximab treatment and prognostic factors for response in patients with Crohn's disease","volume":"94","author":"Mendoza","year":"2002","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1157\/13125587_bb0175","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","article-title":"Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study","volume":"2","author":"Sands","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1157\/13125587_bb0180","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13125587_bb0185","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/gast.2002.35390","article-title":"Predictors of response to infliximab in patients with Crohn's disease","volume":"123","author":"Parsi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1157\/13125587_bb0190","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1365-2036.2003.01574.x","article-title":"An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease","volume":"17","author":"Arnott","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13125587_bb0195","first-page":"2691A","article-title":"Response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn's disease","volume":"94","author":"Lichtenstein","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13125587_bb0200","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10350-004-6611-4","article-title":"Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience","volume":"46","author":"Topstad","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"10.1157\/13125587_bb0205","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1157\/13125587_bb0210","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13125587_bb0215","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1157\/13125587_bb0220","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1157\/13125587_bb0225","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderateto-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1157\/13125587_bb0230","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2036.2006.03232.x","article-title":"Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial","volume":"25","author":"Hinojosa","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1157\/13125587_bb0235","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0210-5705(02)79012-2","article-title":"Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001","volume":"25","author":"Domenech","year":"2002","journal-title":"Gastroenterol Hepatol"},{"key":"10.1157\/13125587_bb0240","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1157\/13072012","article-title":"GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease","volume":"28","author":"Domenech","year":"2005","journal-title":"Gastroenterol Hepatol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570508756449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570508756449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T23:06:53Z","timestamp":1557788813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570508756449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0210570508756449"],"URL":"https:\/\/doi.org\/10.1157\/13125587","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}